phrykt

Voyager Therapeutics, Inc. (VYGR): who owns it and who trades it

As of Nov 16, 2026, VYGR insiders reported 11 open-market sales worth $298K and no purchases in the last 12 months, with 74% of the sale value made under pre-set 10b5-1 plans. The largest seller was Alfred Sandrock (CEO), with $184K. 4 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Voyager Therapeutics

From the latest filings

Overall: more selling than buying. Insiders mostly sold. Funds mostly bought. Famous investors was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns VYGR

135 funds and institutions reported VYGR shares worth $123M at the end of Q2 2026, about 59% of the company. The largest holder is BlackRock, Inc. with 8.7%.

Funds and institutions (13F) 59%Everyone else 41%

10 largest owners, by share of the company

BlackRock, Inc.8.7%
Millennium Management LLC7.5%
Armistice Capital, LLC5.8%
Vestal Point Capital, LP4.4%
Vanguard Capital Management LLC3.9%
Geode Capital Management, LLC2.2%
Opaleye Management Inc.2.0%
State Street Corp1.8%
Two Sigma Investments, LP1.6%
Dimensional Fund Advisors LP1.4%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
BlackRock, Inc.5.17M8.68%$18.1M-7%
Millennium Management LLC4.44M7.45%$15.6M+30%
Armistice Capital, LLC3.44M5.77%$12M-2%
Vestal Point Capital, LP2.62M4.40%$9.2M-13%
Vanguard Capital Management LLC2.35M3.94%$8.2M+3%
Geode Capital Management, LLC1.33M2.23%$4.7M+27%
Opaleye Management Inc.1.19M1.99%$4.1M+3%
State Street Corp1.08M1.81%$3.8M+14%
Two Sigma Investments, LP948,5171.59%$3.3M+54%
Dimensional Fund Advisors LP838,1841.41%$2.9M-4%
Vanguard Portfolio Management LLC810,0911.36%$2.8M+12%
Citadel Advisors LLC784,0671.32%$2.7M+115%
Morgan Stanley697,3341.17%$2.4M+2%
Erste Asset Management GmbH638,9001.07%$2.3M-42%
Renaissance Technologies LLC495,2360.83%$1.7M-14%
Acadian Asset Management LLC428,6700.72%$1.5M+72%
Sphera Funds Management Ltd.427,5540.72%$1.5M-9%
Diadema Partners LP413,6420.69%$1.4M-2%
Northern Trust Corp411,8030.69%$1.4M+7%
AQR Capital Management LLC356,1090.60%$1.2M+53%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, VYGR insiders reported $0 of open-market purchases and $298K of sales. 74% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$298K
11 trades, 4 people
Sales under a 10b5-1 plan
74%
Share of sale value
Latest trade
Apr 2, 2026
Filed Apr 3, 2026

Purchases and sales by month

$253K$253KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Apr 2, 2026Alfred SandrockCEOSale plan11,511$3.87$44.5KForm 4
Feb 24, 2026Robin SwartzCOO & CBOSale plan6,458$3.77$24.3KForm 4
Feb 24, 2026Alfred SandrockCEOSale plan14,197$3.79$53.8KForm 4
Feb 24, 2026Nathan D. JorgensenCFOSale plan4,668$3.77$17.6KForm 4
Feb 24, 2026Todd Alfred CarterChief Scientific OfficerSale plan4,174$3.76$15.7KForm 4
Feb 18, 2026Robin SwartzCOO & CBOSale plan3,882$3.44$13.4KForm 4
Feb 18, 2026Todd Alfred CarterChief Scientific OfficerSale plan3,301$3.44$11.4KForm 4
Feb 18, 2026Alfred SandrockCEOSale plan11,732$3.41$40KForm 4
Feb 10, 2026Robin SwartzCOO & CBOSale4,569$3.85$17.6KForm 4
Feb 10, 2026Alfred SandrockCEOSale12,192$3.78$46.1KForm 4
Feb 10, 2026Todd Alfred CarterChief Scientific OfficerSale3,525$3.85$13.6KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Alfred SandrockPresident and CEO, Director–$184KApr 2, 2026
Robin SwartzCOO & CBO–$55.3KFeb 24, 2026
Todd Alfred CarterChief Scientific Officer–$40.6KFeb 24, 2026
Nathan D. JorgensenChief Financial Officer–$17.6KFeb 24, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

VYGR short interest

Moderate short interest. 7.0% of VYGR shares are sold short: about 1 share in 14. Over the last 12 reports the number of shares short went up 26%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 4.38M VYGR shares were sold short, 7.0% of the shares outstanding, up 20.3% from the report before. At the average daily volume of 1.07M shares, buying them all back would take about 4.1 trading days (days to cover).

Shares short, % of all shares

7.03%May 15Oct 307.22%

Days to cover

4.1May 15Oct 309.6

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20264.38M7.03%+20%1.07M4.1
Oct 15, 20263.64M5.90%-8%906,5394.0
Sep 30, 20263.97M6.45%+9%618,0596.4
Sep 15, 20263.66M5.93%-3%424,4918.6
Aug 31, 20263.79M6.14%-4%426,5558.9
Aug 14, 20263.95M6.40%+8%447,8128.8
Jul 31, 20263.64M5.91%-5%623,3445.8
Jul 15, 20263.84M6.44%+7%838,9854.6
Jun 30, 20263.57M6.00%-2%698,1135.1
Jun 15, 20263.65M6.12%-3%502,8907.2
May 29, 20263.74M6.28%+8%614,8416.1
May 15, 20263.47M5.82%-5%540,8706.4

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Voyager Therapeutics company events

Voyager Therapeutics filed 11 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership). The latest was on Nov 5, 2026.

  1. Nov 5, 2026DealCompleted a purchase or sale of a business or assets. Filing
  2. Oct 21, 2026LeadershipThe Board of Directors of Voyager Therapeutics, Inc. appointed Robin Swartz, the Company’s Chief Business Officer and Chief Operating Officer, to serve as President of the Company, effective immediately. Filing
  3. Aug 6, 2026ResultsReleased financial results. Filing
  4. Jul 13, 2026AnnouncementVoyager Therapeutics, Inc. presented good laboratory practice toxicology data for VY1706, the Company’s investigational tau silencing gene therapy developed to target intracellular and extracellular tau for Alzheimer’s disease, at the Alzheimer’s Association International Conference. Filing
  5. Jun 10, 2026VoteReported shareholder vote results. Filing
  6. Jun 1, 2026AnnouncementVoyager Therapeutics, Inc. announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application for VY1706, the Company’s investigational tau silencing gene therapy developed to target intracellular and extracellular tau for Alzheimer’s disease. Filing
  7. May 7, 2026ResultsReleased financial results. Filing
  8. Apr 21, 2026LeadershipNathan Jorgensen, Ph.D. notified Voyager Therapeutics, Inc. of his decision to resign from his position as Chief Financial Officer of the Company and from any and all other positions he holds with the Company and any of its subsidiaries, effective May 8, 2026 (the effective time of Dr. Jorgensen’s… Filing
  9. Mar 9, 2026ResultsReleased financial results. Filing
  10. Feb 12, 2026LeadershipToby Ferguson, M.D., Ph.D. notified Voyager Therapeutics, Inc. of his decision to resign from his position as Chief Medical Officer of the Company and from any and all other positions he holds with the Company and any of its subsidiaries, effective February 20, 2026, to pursue a new opportunity. Filing
  11. Jan 8, 2026AnnouncementShared information with investors. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Voyager Therapeutics financials

Famous investors that hold VYGR

4 of the 50 well-known investors we track reported holding VYGR in their latest 13F filing. The largest position is Israel Englander's, worth $13.1M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Israel Englander · Millennium ManagementQ3 20264.88M$13.1M0.0%+10%
Jim Simons · Renaissance TechnologiesQ3 2026406,604$1.1M0.0%-18%
Ken Griffin · Citadel AdvisorsQ3 2026323,918$868K0.0%-59%
Steve Cohen · Point72 Asset ManagementQ3 2026278,800$747K0.0%+18%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named VYGR in the last 120 days.

FiledHolderFormStake
Nov 16, 2026Armistice Capital, LLC13G6.3%
Nov 16, 2026Armistice Capital, LLC13G6.3%
Nov 16, 2026Armistice Capital, LLC13G/A1.3%
Nov 16, 2026Armistice Capital, LLC13G/A1.3%

Questions about Voyager Therapeutics, Inc. (VYGR) stock

Who owns the most VYGR stock?

The largest reported owner of Voyager Therapeutics, Inc. (VYGR) is BlackRock, Inc., with 8.7% of the company. In total, 135 funds and institutions reported holding VYGR at the end of Q2 2026, together about 59% of the shares. See the largest owners.

Are VYGR insiders buying or selling?

In the last 12 months, VYGR insiders reported no open-market purchases and 11 sales worth $298K. The latest trade was on Apr 2, 2026. See every trade.

What is the short interest in VYGR?

As of Oct 30, 2026, 4.38M VYGR shares were sold short, 7.0% of the shares outstanding, up 20.3% from the report before. At the average daily volume of 1.07M shares, buying them all back would take about 4.1 trading days (days to cover). See the history.

Which famous investors hold VYGR?

4 of the 50 well-known investors we track reported VYGR in their latest 13F filing, including Israel Englander, Jim Simons, Ken Griffin. The largest position is worth $13.1M. See all holders.

Executive pay

Voyager Therapeutics's chief executive was paid a total of $2.5M for the year ended Dec 31, 2025, down 26% from $3.4M the year before. In the last 12 months, Voyager Therapeutics's executives and directors bought no stock on the open market and sold $298K.

Chief executive, total pay$2.5MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$2.1MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$1.4MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.